Key Financial Performance - Consolidated

  • Revenue from Operations: ₹240 Crore, representing a 24.3% year-on-year (YoY) growth.
  • EBITDA: ₹77.27 Crore, with a margin of 32.2% (226 basis points improvement YoY).
  • Profit After Tax (PAT): ₹51.33 Crore, representing a 34.1% YoY growth.
  • Earnings Per Share (EPS): ₹3.23, up 34.0% YoY.
  • Gross Margin: 74.1%, an improvement of 292 basis points YoY.

Key Financial Performance - Standalone (TTL)

  • Revenue from Operations: ₹225.66 Crore, up 26.1% YoY.
  • EBITDA: ₹75.60 Crore, with a margin of 33.5% (191 basis points improvement YoY).
  • Profit After Tax (PAT): ₹50.17 Crore, up 39.2% YoY.
  • Earnings Per Share (EPS): ₹3.15, up 39.1% YoY.
  • Breakdown of standalone revenue growth: Franchisee segment grew 27% YoY, Partnerships segment grew 26% YoY, and Direct-to-Consumer (D2C) segment grew 17% YoY.

Operational and Business Metrics

  • Quarterly Active Franchisees: Reached a record 11,730, with approximately 900 additions in Q1 FY27, noted as the highest quarterly addition in 3 years.
  • Patients Served: 5.4 Million, a 17% increase YoY.
  • Tests Conducted: 55.2 Million, a 28% increase YoY. The definition of a 'test conducted' was revised from Q1 FY27 to exclude calculated parameters. Restated numbers for previous quarters were provided.
  • Test Menu Offerings: 1,375 tests.
  • Quality Metrics: 97% of samples were processed in NABL Accredited labs. Complaints per million tests were 3.1, a 24% reduction YoY.
  • New Technology Additions: Gut Microbiome and Whole Exome sequencing were added to the service portfolio.

Subsidiary Performance - Radiology Business

  • Revenue from Operations: ₹13.48 Crore, a decline of 4.0% YoY, attributed to a strategic exit from non-profitable centers.
  • EBITDA: ₹2.65 Crore, a growth of 23.1% YoY.
  • Profit After Tax (PAT): ₹1.72 Crore, a significant growth of 379% YoY, driven by lower depreciation following center closures.
  • This business consists of Nuclear healthcare and Pulse Hi tech businesses.

Strategic Initiatives and Updates

  • New Launches: A new Regional Processing Laboratory was launched in Muzaffarpur, and Hybrid labs were launched in Prayagraj and Kurnool to strengthen the testing network and improve turnaround times.
  • Stakeholder Engagement: Conducted franchisee meetings to capture feedback and strengthen processes. Conducted 23 doctor meetings, capturing feedback from approximately 100 doctors.
  • Awards: Thyrocare was honored with the "India's Most Trusted Customer-Focused Diagnostic Brand – 2026" award at the Pride of Healthcare Excellence Awards & Summit 2026. It also won "Diagnostic Chain of the Year" and "Pathology Lab Chain of the year" at the Financial Express Healthcare Awards 2026.

Expenses Commentary

Employee benefit expenses increased YoY due to annual increments and the expansion of Labs and Specialty Diagnostics. This includes the parent company's ESOP charge. Other expenses also saw an increase.

Growth Strategy and Outlook

The presentation outlines a multi-pronged growth strategy with four key pillars:

1. Franchise Network Strengthening: Investing in expansion and development through training.

2. Institutional Partnerships: Broadening collaborations with health-tech, corporates, and insurance providers.

3. Routine to Remarkable: Expanding specialty offerings in advanced pathology, genomics, and biomarker-based diagnostics.

4. Scientific Engagement: Deepening clinician outreach and scientific engagement to build trust.

The company's pathology strategy is to be a B2B service provider with an affordable, value-driven model based on scale efficiencies. The Direct-to-Consumer (D2C) business currently constitutes 5% of the business.